Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about the latest prostate cancer clinical trial results and treatment advances from the 2025 European Society for Medical Oncology (ESMO) conference in this 26-minute medical education video. Discover key findings from three pivotal randomized phase III trials that are reshaping prostate cancer treatment protocols. Explore the PSMA Addition trial results showing how LuPSMA-617 combined with androgen receptor pathway inhibitors (ARPI) and androgen deprivation therapy (ADT) improves radiographic progression-free survival compared to standard abiraterone plus ADT in first-line metastatic castration-sensitive prostate cancer. Examine the CAPItello-281 study demonstrating that capivasertib, an AKT inhibitor, when added to abiraterone and ADT, significantly improves outcomes in PTEN-deficient metastatic castration-sensitive prostate cancer patients. Review the EMBARK trial findings revealing how enzalutamide combined with ADT enhances metastasis-free survival and overall survival in high-risk biochemical relapse cases detected through conventional imaging. Gain insights into radioligand therapy applications, targeted treatment approaches for specific genetic markers, and evidence-based strategies for managing different stages of prostate cancer progression.
